---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-040930"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2026-09-01T12:00:25+00:00"
generated_at: "2026-09-01T12:05:12.923819+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MIRA Pharmaceuticals reports positive toxicology results for MIRA-55; targets Q1 2027 IND

## Summary
- 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs completed with positive results.
- Rats identified as more sensitive species; dogs showed greater tolerance; systemic exposure confirmed in both.
- Results inform dose selection for next phase of IND-enabling program; GLP-compliant studies planned.
- Company targets IND submission to FDA for MIRA-55 in Q1 2027, subject to remaining studies.
- MIRA-55 is an oral non-opioid candidate for inflammatory pain; DEA has determined it is not a controlled substance.

## SEC filing metadata
- accession: 0001493152-26-040930
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2026-09-01T12:00:25+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315226040930/0001493152-26-040930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315226040930/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-040930
- JSON: https://secwatch.observer/filing/0001493152-26-040930.json
- Plain text: https://secwatch.observer/filing/0001493152-26-040930.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.